ResistAid®

Referências:

1. 30. Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Curr Med Res Opin. 2013;29(3):251–8.

 

2. Udani JK. Immunomodulatory effects of ResistAid: a randomized, doubleblind, placebo-controlled, multidose study. J Am Coll Nutr. 2013;32(5):331–8.doi:10.1080/07315724.2013.839907.

 

3. Kim LS, Burkholder PM, Waters RF. Effects of low-dose larch arabinogalactan from larix occidentalis: a randomized, double-blind, placebo-controlled pilot study. Complement Health Pract Rev. 2002;7(3): 221–9. doi:10.1177/153321010200700305.

 

4. Grieshop CM, Flickinger EA, Fahey Jr GC. Oral administration of arabinogalactan affects immune status and fecal microbial populations in dogs. J Nutr. 2002;132(3):478–82.

 

5. Marzorati M, Verhelst A, Luta G, Sinnott R, Verstraete W, Van de Wiele T, et al. In vitro modulation of the human gastrointestinal microbial community by plant-derived polysaccharide-rich dietary supplements. Int J Food Microbiol. 2010;139(3):168–76. doi:10.1016/j.ijfoodmicro.2010.02.030.

 

6. Kim LS, Waters RF, Burkholder PM. Immunological activity of larch arabinogalactan and Echinacea: a preliminary, randomized, double-blind, placebo-controlled trial. Altern Med Rev. 2002;7(2):138–49.

 

7. Grube B, Stier H, Riede L, Gruenwald L. Tolerability of a proprietary larch arabinogalactan extract: a randomized, double-blind, placebo-controlled clinical trial in healthy subjects. Food Nutr Scie. 2012;3:1533–8.